Neuronetics Overcomes Negative Panel Review To Earn Clearance For NeuroStar
This article was originally published in The Gray Sheet
Executive Summary
FDA cleared Neuronetics' NeuroStar transcranial magnetic stimulation system for drug-resistant depression, despite a negative advisory panel review, based on a pivotal study subset analysis
You may also be interested in...
New Products In Brief
Medtronic’s Endurant II AAA stent graft, Quest’s thyroid cancer test services and new Covidien Endo GIA staplers are among devices making market debuts.
Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy
Despite a recent negative Blue Cross Blue Shield technology assessment, Neuronetics is moving ahead with plans to expand sales and marketing efforts for its NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression.
Neuronetics Plans Expanded Marketing For Transcranial Magnetic Stimulation Depression Therapy
Despite a recent negative Blue Cross Blue Shield technology assessment, Neuronetics is moving ahead with plans to expand sales and marketing efforts for its NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression.